Related Experiment Video
Updated: Mar 13, 2026

Purification of the Membrane Compartment for Endoplasmic Reticulum-associated Degradation of Exogenous Antigens in Cross-presentation
Published on: August 21, 2017
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation:
Anna E Kersh1, Maiko Sasaki2, Lee A Cooper3
1Medical Scientist Training Program, Emory University School of Medicine Atlanta, GA, USA.
Abstract:
Advances in molecular pathology have changed the landscape of oncology. The ability to interrogate tissue samples for oncogene amplification, driver mutations, and other molecular alterations provides clinicians with an enormous level of detail about their patient's cancer. In some cases, this information informs treatment decisions, especially those related to targeted anti-cancer therapies. However, in terms of immune-based therapies, it is less clear how to use such information. Likewise, despite studies demonstrating the pivotal role of neoantigens in predicting responsiveness to immune checkpoint blockade, it is not known if the expression of neoantigens impacts the response to targeted therapies despite a growing recognition of their diverse effects on immunity. To realize the promise of 'personalized medicine', it will be important to develop a more integrated understanding of the relationships between oncogenic events and processes governing anti-tumor immunity. One area of investigation to explore such relationships centers on defining how ErbB/HER activation and signal transduction influences antigen processing and presentation.
Insights
Molecular pathology advances cancer treatment. Understanding how oncogenic events like ErbB/HER activation influence anti-tumor immunity and neoantigen presentation is key for personalized medicine.
Area of Science:
- Oncology
- Molecular Pathology
- Immunology
Background:
- Molecular pathology provides detailed cancer insights, guiding targeted therapies but leaving immune-based treatments less defined.
- The role of neoantigens in predicting response to immune checkpoint blockade is known, yet their impact on targeted therapies remains unclear.
- Personalized medicine requires integrating oncogenic events with anti-tumor immunity processes.
Approach:
- Investigating the relationship between oncogenic events and anti-tumor immunity.
- Focusing on how ErbB/HER activation and signal transduction pathways affect antigen processing and presentation.
Key Points:
- Molecular alterations in cancer inform targeted therapy but not immune therapy.
- Neoantigen expression's impact on targeted therapy response is unknown.
- ErbB/HER pathway activation influences antigen processing and presentation.
Conclusions:
- Further research is needed to integrate molecular alterations with anti-tumor immunity for effective personalized cancer care.
- Understanding ErbB/HER signaling's role in antigen presentation is crucial for developing novel immunotherapies.
Related Concept Videos
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Mitogens and the Cell Cycle
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...

